Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 4 2Phase 2 1

Status

Withdrawn 2Completed 2Terminated 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 3Tumor-Agnostic 1

Conditions

Carcinoma, Basal Cell 2Neoplasms 1Melanoma 1Exanthema 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Acitretin × Clear all
NCT02050321 2018-12-26

A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma

University of Arizona

Phase 2 Terminated
2 enrolled 7 charts
Dermatologic

Melanoma

NCT00488384 2018-07-19

Acitretin Plasma Levels Under Hemodialysis

University of Zurich

Phase 4 Withdrawn
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00003611 2016-07-13

Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation

Alliance for Clinical Trials in Oncology

Phase NA Completed
129 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT01299220 2013-01-16

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

University of Pittsburgh

Phase 4 Withdrawn

Exanthema, Neoplasms

NCT00644384 2011-05-16

Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer

Mayo Clinic

Phase NA Completed
130 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡